Foresite Capital

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally delivered small-molecule therapies for oncology and inflammatory diseases. It uses a proprietary discovery and development engine to create highly selective compounds that modulate immune responses. The company's lead oncology candidate, FLX475, targets the C-C motif chemokine receptor 4 and is in a Phase 1/2 program as monotherapy and in combination with pembrolizumab. The lead inflammation candidate, RPT193, is designed to selectively inhibit migration of type 2 T helper cells into inflamed tissues. Additional targets such as general control nonderepressible 2 and hematopoietic progenitor kinase 1 are in discovery. Founded in 2015 and headquartered in South San Francisco, the company aims to address unmet medical needs in cancer and inflammatory diseases.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

MyOme develops a genetic testing technology that provides comprehensive health insights through whole genome sequencing. Its platform offers detailed reports on disease risk and medication response, accompanied by independent physician reviews and genetic counseling. The company ensures ongoing updates using advanced technologies, empowering individuals to make informed health decisions while maintaining data privacy and security.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

TenSixteen Bio is a biotechnology company dedicated to developing innovative therapeutics targeting various diseases. It leverages somatic mosaicism and clonal hematopoiesis (CHIP) to discover and advance treatments for age-related disorders.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Velia operates a biotechnology platform designed to propel the advancement of targeted therapies. It offers extensive genomic and proteomic data analysis, sophisticated bioinformatics, and customizable research tools, empowering pharmaceutical and biotech companies to expedite drug discovery and development.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTR™ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

XinThera is a drug discovery company dedicated to developing precision medicines for the treatment of cancer and immunologic diseases. The company utilizes advanced computational chemistry technologies to design small molecule therapies aimed at well-validated targets that are often considered challenging in oncology and immunology. By focusing on these promising targets, XinThera strives to provide effective drug therapies that can address unmet medical needs for patients suffering from these conditions.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Founded in 2006, 23andMe is a biotechnology company specializing in direct-to-consumer genetic testing. It offers DNA analysis services through home-based saliva collection kits, providing insights into ancestry, traits, and health risks.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTR™ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

Founded in 2020, Sestina Bio is a biotechnology company dedicated to developing innovative synthetic biology platforms. The company aims to tackle global challenges by integrating advanced technologies such as synthetic biology, data sciences, and bio-analytical systems.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Nurix Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing oral small-molecule therapies that modulate cellular protein levels to treat cancer and immune disorders. It operates DELigase, an integrated discovery platform that targets E3 ligases to alter protein abundance within cells. The company's product pipeline includes targeted protein degraders such as NX-2127, an oral Bruton's tyrosine kinase degrader for relapsed or refractory B-cell malignancies, and NX-1607, an oral Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications; these are in preclinical stages. Nurix also explores inhibitors of CBL-B, an E3 ligase that regulates T cell activation. The company collaborates with major industry partners, including Gilead Sciences and Sanofi, and was founded in 2009 and is headquartered in San Francisco.

Vaxcyte is a biotechnology company developing vaccines to prevent or treat infectious diseases worldwide. Its lead product is VAX-24, a 24-valent pneumococcal conjugate vaccine candidate. The company also develops vaccines targeting emerging strains of pneumococcal disease (VAX-XP), Group A Strep infections (VAX-A1), and periodontal disease (VAX-PG).

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment. The company specializes in neoantigen-specific adoptive T-cell therapies aimed at solid tumors. Its innovative platform utilizes bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying candidate neoantigen peptides that stimulate robust antitumor T-cell responses. By pinpointing neo-epitopes unique to each patient's cancer, PACT Pharma enables the engineering of autologous T cells that specifically target and eradicate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is dedicated to advancing personalized medicine in oncology.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Vaxcyte is a biotechnology company developing vaccines to prevent or treat infectious diseases worldwide. Its lead product is VAX-24, a 24-valent pneumococcal conjugate vaccine candidate. The company also develops vaccines targeting emerging strains of pneumococcal disease (VAX-XP), Group A Strep infections (VAX-A1), and periodontal disease (VAX-PG).

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Juvenescence is a British Virgin Islands-based company focused on investing in human aging and longevity. It aims to extend both lifespan and healthspan by developing therapeutics that slow aging and treat age-related diseases. The company creates and partners with new ventures, in-licenses compounds, or forms joint ventures to build an ecosystem of assets targeting aging, regeneration, and related diseases.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its products include Chromium platforms for single-cell gene expression analysis, immune profiling, epigenetics study, and spatial gene expression measurement. Serving academic, government, biopharmaceutical, and other institutions globally.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

Intellia Therapeutics, Inc. is a genome editing company headquartered in Cambridge, Massachusetts, specializing in the development of therapeutics using the CRISPR/Cas9 technology. This innovative platform allows for precise alterations of genomic DNA, enabling the company to pursue treatments for a range of severe and life-threatening diseases. Intellia's pipeline includes both in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as ex vivo programs focused on engineered cell therapies for oncological and autoimmune disorders. The company is also exploring treatments for conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Intellia has established collaborations with several organizations, enhancing its research and development capabilities. Founded in 2014, Intellia holds a significant intellectual property portfolio related to the therapeutic applications of CRISPR/Cas9, aiming to address high unmet medical needs through its advanced gene-editing approaches.

Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, designing, optimizing, and producing stereopure oligonucleotides through its PRISM platform. The company aims to address genetically defined diseases by reducing harmful protein expression or correcting dysfunctional proteins, employing modalities such as RNA editing, antisense silencing, and RNA interference. Its programs span neurological and neuromuscular conditions, reflecting an emphasis on central nervous system targets. Wave collaborates with Pfizer and Takeda on research, development, and commercialization of stereopure oligonucleotide therapeutics and antisense therapies. Founded in 2012 and based in Singapore, the company seeks to unlock the broader potential of RNA medicines to improve patient outcomes.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Aimmune Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for peanut and other food allergies. The company’s primary product candidate, PALFORZIA, utilizes a therapeutic approach known as Characterized Oral Desensitization Immunotherapy (CODIT) to desensitize patients to food allergens. Aimmune is also engaged in research and development of additional CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergy in pediatric and young adult populations, as well as other candidates targeting allergies like cow's milk. The company collaborates strategically with Nestlé Health Science to advance food allergy therapeutics and has clinical agreements with Regeneron and Sanofi to study PALFORZIA in conjunction with dupilumab for peanut-allergic patients. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics was previously known as Allergen Research Corporation before rebranding in 2015 and is now a subsidiary of Société des Produits Nestlé S.A.

Aduro Biotech is a clinical-stage biopharmaceutical company focused on developing immunotherapies to harness the body's natural immune system for treating challenging diseases. Its pipeline includes ADU-S100, in Phase I/II trials for various solid tumors and head & neck cancer, and BION-1301, a monoclonal antibody in Phase I trial for IgA nephropathy.

10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its products include Chromium platforms for single-cell gene expression analysis, immune profiling, epigenetics study, and spatial gene expression measurement. Serving academic, government, biopharmaceutical, and other institutions globally.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative treatments for central nervous system (CNS) disorders. The company's lead product, ZULRESSO, is an intravenous formulation of brexanolone specifically designed for the treatment of postpartum depression. SAGE Therapeutics is advancing a diverse product pipeline, including SAGE-217, a novel neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and other neurological conditions. Additionally, SAGE-718, an oxysterol-based positive allosteric modulator, has completed Phase I trials targeting multiple CNS-related disorders. The company also explores other compounds, such as SAGE-904 and SAGE-689. SAGE Therapeutics has established strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates, emphasizing its commitment to addressing the challenges of brain health.

Sequenta is a biotechnology company focused on the development of clinical diagnostics that leverage innovative methods to assess immune system status. Founded in 2008 by previous entrepreneurs from ParaAllele BioScience, Sequenta employs advanced techniques to analyze the immune cell receptor genes, which exhibit significant variability in the human genome. This diversity is critical for understanding various health conditions and diseases, enabling Sequenta to provide insights that may influence numerous clinical decisions through a single, powerful assay. The company's approach capitalizes on the reduced costs of DNA sequencing, positioning Sequenta at the forefront of advancements in immune-related diagnostics.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.